Axel Mescheder, MD, CDO/CMO
Axel Mescheder was appointed Chief Development Office and Chief Medical Officer (CDO/CMO) of Lanthio in 2016. He has more than 20 years of experience in R&D management positions in the pharmaceutical and biotechnology industry. He has demonstrated the ability to successfully develop, implement and drive clinical development programs and has a track record of advancing a number of compounds through the various clinical phases that lead to product registration or label extensions, either in Europe or in the US. He joins Lanthio Pharma from Medpace GmbH, Munich/Germany, where he acted as Vice President Medical & Regulatory Affairs Europe. Prior to that, he held the positions of Chief Medical and Development Officer at TopoTarget A/S, Copenhagen/Denmark, and Medigene AG, Munich/Germany. From 2001 to 2003 he worked at MorphoSys AG as a Medical Director. Prior to that, Dr. Mescheder held various management positions in research and development at Genetics Institute/Wyeth-Ayerst Research (Pfizer), Centeon (CSL Behring) and Hoffmann-La Roche. He holds an M.D. from Christian-Albrechts-University in Kiel, Germany, specializing in pharmacology and toxicology.